Funder
U.S. Food and Drug Administration's Critical Path Initiative
U.S. Food and Drug Administration's Office of Women's Health
Subject
Cardiology and Cardiovascular Medicine
Reference23 articles.
1. Guideline for Industry E14 Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-antiarrhythmic Drugs;International Council on Harmonisation,2005
2. Dealing with global safety issues: was the response to QT-liability of non-cardiac drugs well coordinated?;Stockbridge;Drug Saf,2013
3. Drug-induced prolongation of the QT interval;Roden;N Engl J Med,2004
4. Early afterdepolarizations: mechanism of induction and block. A role for L-type Ca2+ current;January;Circ Res,1989
5. ICH Topic S7B the Nonclinical Evaluation of the Potential for Delayed Ventricular Repolarization (QT Interval Prolongation) by Human Pharmaceuticals;International Council on Harmonisation,2005
Cited by
18 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献